Use of procalcitonin for antibiotic stewardship in patients with COVID-19: A quality improvement project in a district general hospital

Clin Med (Lond). 2021 Jan;21(1):e71-e76. doi: 10.7861/clinmed.2020-0614. Epub 2020 Dec 18.

Abstract

Antibiotic stewardship during the COVID-19 pandemic is an important part of a comprehensive strategy to improve patient outcomes and reduce long-term adverse effects secondary to rising antibiotic resistance. This report describes a quality improvement project which incorporates the use of procalcitonin (PCT) testing to rationalise antibiotic prescribing in patients with suspected or confirmed COVID-19 at Chesterfield Royal Hospital. Data were collected from 118 patients with a total of 127 PCT levels checked over a period of 20 days. Each PCT level was correlated with the subsequent antibiotic outcome as well as the result of the COVID-19 PCR swab. Results indicate that antibiotics were either never started or were stopped within 48 hours in 72% of COVID-confirmed cases with a PCT less than 0.25 μg/L. Our findings suggest that procalcitonin testing, when used in combination with thorough clinical assessment, is a safe, simple and sustainable way of reducing antibiotic use in COVID-19.

Keywords: COVID-19; antibiotic stewardship; bacterial resistance; procalcitonin; quality improvement.

MeSH terms

  • Anti-Bacterial Agents / therapeutic use*
  • COVID-19 / epidemiology
  • COVID-19 / virology
  • COVID-19 Drug Treatment*
  • Drug Resistance, Bacterial / drug effects*
  • Female
  • Follow-Up Studies
  • Hospitals, District*
  • Humans
  • Male
  • Middle Aged
  • Pandemics
  • Procalcitonin / therapeutic use*
  • RNA, Viral / analysis*
  • Retrospective Studies
  • SARS-CoV-2 / genetics*

Substances

  • Anti-Bacterial Agents
  • Procalcitonin
  • RNA, Viral